A. baumannii is a common aerobic, pleomorphic, and inactive Gram-negative bacillus that is ubiquitous in the environment. It is an opportunistic pathogen that is usually harmless to healthy individuals but has a higher incidence in immunocompromised individuals. Nosocomial infections caused by multidrug-resistant A. baumannii are becoming more common worldwide, especially in intensive care units. A. baumannii infection causes diarrhea, bacteremia, lung infection, meningitis, etc.
The acquired drug resistance mechanism of A. baumannii is diverse, mainly including the following aspects: 1) the strain produces an inactivating enzyme to inactivate the antibiotic; 2) changes the site of action of the antibiotic; 3) the intracellular drug concentration decreases. Among them, the high expression of bacterial efflux pump genes and the decrease of the permeability of bacterial outer membrane porins play a key role; 4) the formation of bacterial biofilm.
Fig.1 Schematic representation of capsule polysaccharide assembly and export in A. baumannii. (Singh, et al., 2019)
Vaccines are an effective way to prevent microbial infections while simultaneously reducing disease burden, disability, patient mortality, and healthcare costs. As a professional Glyco™ Vaccine Development company, CD BioGlyco has established an advanced Polysaccharide Vaccine Development platform to provide clients with high-quality polysaccharide vaccine development services against a variety of pathogenic microorganisms. Bacterial surface carbohydrates play a key role in the overall fitness and virulence of A. baumannii. The capsular polysaccharide (CPS) is an antigenic component consisting of tightly packed repeating oligosaccharide subunits (K units) located in the outermost layer of A. baumannii. It helps evade host immune defenses and increases resistance to a variety of antimicrobial compounds. CPS has been used in the development of various vaccines and novel phage therapies. Such as conjugating CPS with carrier proteins to develop Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis vaccines.
Currently, more than 20 A. baumannii CPS structures have been identified. Due to the high diversity of its K sites, more than 90 serotypes of A. baumannii are predicted. We provide our clients with CPS production service on the surface of A. baumannii. We extract crude bacterial CPS from A. baumannii using the phenol-water method and purify it by column chromatography. According to the needs of clients, we conjugate the structurally determined CPS with the target Carrier Protein to obtain CPS-carrier protein conjugates.
Fig.2 Flowchart of polysaccharide antigen production. (CD BioGlyco)
CD BioGlyco provides you with a One-stop Polysaccharide Conjugation Service, including carrier protein design, Polysaccharide Production, and polysaccharide-carrier protein conjugation. Our experienced experts will help you solve the difficulties and problems in development. If you have a polysaccharide vaccine development project in hand, please contact us in time for more information.
Reference:
